Skip to main content

Table 3 Treatment response and oncological outcome

From: Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03)

Patient Tumor site, histology and size Sunitinib dose RT dose Resection margin RECIST % non-viable tissue Follow-up status (and time), events (months after ED)
1 lower extremity, myxofibrosarcoma, 11 cm 25 50.4 R0 stable disease 30 % NED (29mo), LR resected (19 mo)
2 lower extremity, dediff. lipo, 8 cm 25 50.4 R0 stable disease 95 % AWD (36 mo), Soft tissue mets (15 mo)
3 Retroperitoneal, dediff. lipo, 15 cm 25 50.4 R1 stable disease 75 % NED (28 mo)
4 Retroperitoneal, dediff. lipo, 12 cm 25 50.4 R1 stable disease 20 % NED (11 mo)
5 Retroperitoneal, undiff. pleomorphic sarcoma, 14 cm 25 50.4 R2 (primary Tumor R0) progressive disease (locally and mets) 70 % DOD (9 mo), Liver mets at surgery
6 Groin, Dediff. lipo, 20 cm 25 50.4 R0 stable disease 30 % NED (24 mo)
7 Retroperitoneal, myxoidlipo, 5 cm 37.5 50.4 R0 partial response 50 % NED (20 mo)
8 lower extremity, synovial sarcoma, 8 cm 37.5 50.4 R0 stabledisease 100 % AWD (23 mo), Lung mets (15 mo)
9 chest wall, undiff. pleomorphic sarcoma, 5 cm 37.5 50.4 R0 stabledisease 100 % NED (13 mo)